YARW:NASDAQ, Yarrow Bioscience Inc Com Par $ New
Why YARW stock rose on November 11
Yarrow Bioscience Inc Com Par $ New rose 16.6%
on Wednesday, November 11, 2026, on 187,300 shares.
No headline about YARW came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
YARW stock overview
Yarrow Bioscience Inc Com Par $ New (YARW:NASDAQ) closed at $18.03 on November 13, 2026,
down 8.15% on the day.
The stock trades 61.6% below its 52-week high of $46.95
and 45.6% above its 52-week low of $12.39.
Over the past year, it lost 2.8%.
Yarrow Bioscience Inc Com Par $ New is part of the Health Care sector.
Key figures
- Price
- $18.03
- Day change
- -8.15%
- Volume
- 99,111
- Average volume
- 140,381
- Market cap
- 167M+
- 52-week range
- $12.39 – $46.95
- 50-day average
- $22.09
- 200-day average
- $30.23
Price action over the past year
In 252 trading sessions since November 13, 2025, YARW closed higher on 129 days (51%).
Its best day was December 17, 2025 (+48.88%) and its worst was July 24, 2026 (-44.85%).
The stock moved 10% or more in a single session 12 times.
It opened at least 5% above the previous day's high 1 time.
Recent signals
YARW news
-
Nov 12, 2026:
Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update
-
Nov 6, 2026:
Guggenheim starts Yarrow Bioscience at Buy, citing Graves disease potential
-
Nov 6, 2026:
Molson Coors downgraded, SiTime upgraded: Wall Street's top analyst calls
-
Nov 2, 2026:
Yarrow Bioscience Announces Participation in November Investor Events
-
Sep 14, 2026:
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters Option to Purchase Additional Shares
-
Sep 14, 2026:
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Sep 11, 2026:
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
-
Sep 10, 2026:
Yarrow Bioscience Announces Proposed Underwritten Public Offering
About Yarrow Bioscience Inc Com Par $ New
Yarrow is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases.
Similar stocks
Find more stocks like YARW with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.